The Development Office’s Corporate and Foundation (C&F) Team identified the below funding opportunities. To apply, please contact DevCorpFound@mountsinai.org. The C&F team will help plan, write, and submit your application.
| Alzheimer’s Drug Discovery Foundation: Accelerating Drug Discovery for Frontotemporal Degeneration | Amount: Up to $300,000 over 1 year | Deadline: • LOI due May 11, 2026 • Full proposal due July 20, 2026 |
Eligibility: — | About: The Alzheimer’s Drug Discovery Foundation (ADDF) and The Association for Frontotemporal Degeneration (AFTD) seek to accelerate this progress by supporting innovative small molecule and biologic (antibodies, oligonucleotides, peptides, gene therapy etc.) drug development programs for FTD through this request for proposals (RFP). The RFP supports: • Lead optimization of novel disease-modifying compounds, including medicinal chemistry refinement and in vitro ADME. • In vivo testing of novel lead compounds, biologics, vaccines or repurposed drug candidates in relevant animal models for pharmacokinetics, dose-range finding, target engagement, in vivo efficacy, and/or preliminary rodent tolerability studies. |
Request for Proposals: Accelerating Drug Discovery for Frontotemporal Degeneration | Alzheimer’s Drug Discovery Foundation |
| ADDF-Harrington Scholar Program | Amount: $600,000 over 2 years | Deadline: • LOI due June 1, 2026 • Full proposal due August 17, 2026 |
Eligibility: • Lead investigator must have an MD, a PhD, or equivalent. • Proposals should show potential to advance discovery into meaningful therapeutics to treat, prevent, slow, or reverse Alzheimer’s disease or related dementias (vascular dementia, frontotemporal dementia, Lewy Body dementia, LATE etc). • Team should possess intellectual property (IP) or have potential for novel IP that has not yet been licensed to a for-profit entity. • Researchers working on drug development programs that are relevant to but not presently focused on the Alzheimer’s field are strongly encouraged to apply. |
About: The ADDF-Harrington Scholar Program is dedicated to advancing academic discoveries into medicines for Alzheimer’s disease and related dementias. This award provides funding and project support by a team of pharmaceutical industry experts through a collaboration with the Alzheimer’s Drug Discovery Foundation (ADDF) and the Brain Health Medicines Centers of the Harrington Discovery Institute. | ADDF-Harrington Scholar Program | Alzheimer’s Drug Discovery Foundation |
| American Cancer Society: Clinician Scientist Development Grant | Amount: $675,000 over 5 years | Deadline: June 1, 2026 | Eligibility: • Have a doctoral degree, an active clinical license, and participate in clinical care • Are not a current or former principal investigator (PI) of an individual mentored training grant • Have NOT had an R-level or equivalent grant as PI |
About: The Clinician Scientist Development Grant (CSDG) supports full-time faculty members in becoming independent investigators as clinician scientists. This grant is designed for people trained primarily as clinicians who want to maintain clinical practice and conduct cancer research. | Clinician Scientist Development Grant | American Cancer Society |
| American Cancer Society: Research Scholar Grants | Amount: $860,000 over 4 yrs | Deadline: June 1, 2026 | Eligibility: You ARE eligible to submit a proposal if you: • Were first appointed as independent, full-time faculty LESS than 10 years ago • Are the PI on NO MORE than 1 R01 or R01-equivalent grant at the time of application |
About: Research Scholar Grants (RSG) provide support for independent, self-directed researchers. Grant proposals are investigator-initiated and may pursue questions across the cancer research continuum, as long as they fit within an American Cancer Society (ACS) priority research area. | Cancer Research Scholar Grants | American Cancer Society |
| Weiss Asset Management Foundation: Programs and Research to Alleviate Human Suffering | Amount: Up to $1.5M over 3 years | Deadline: Rolling | Eligibility: — | About: The mission of Weiss Asset Management Foundation is to reduce human suffering globally. With an Allocation Committee composed of development economists and practitioners, we support evidence-based, cost-effective programs and research that we believe will yield a high, risk-adjusted social return on investment. Examples of prior grants include support for evidence-based nutrition programming for children suffering from severe acute malnutrition, policy-oriented research to reduce barriers to vaccination programs, and technical assistance for government water-purification efforts. We welcome all proposals related to our goal of reducing human suffering globally. We expect most grants to fall into the following two categories: • Project-based Support: We support work for specific initiatives. o Research with high potential for impact on policy or programs; o Technical assistance; o Operational innovations and experiments for unique programmatic opportunities; and o Support for proven, cost-effective programs that face funding gaps. o Note: For research proposals, we prioritize rigorous causal identification, data science for targeting, and important monitoring or descriptive work that could lead to action. We deprioritize simple correlations or purely qualitative work. • General Support: We also provide general support for highly cost-effective organizations or programs. |
Request for Proposals | Weiss Asset Management Foundation | Alleviating Suffering Worldwide |